These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19640287)

  • 1. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
    Ribas A; Kirkwood JM; Atkins MB; Whiteside TL; Gooding W; Kovar A; Gillies SD; Kashala O; Morse MA
    J Transl Med; 2009 Jul; 7():68. PubMed ID: 19640287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
    King DM; Albertini MR; Schalch H; Hank JA; Gan J; Surfus J; Mahvi D; Schiller JH; Warner T; Kim K; Eickhoff J; Kendra K; Reisfeld R; Gillies SD; Sondel P
    J Clin Oncol; 2004 Nov; 22(22):4463-73. PubMed ID: 15483010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer.
    Ko YJ; Bubley GJ; Weber R; Redfern C; Gold DP; Finke L; Kovar A; Dahl T; Gillies SD
    J Immunother; 2004; 27(3):232-9. PubMed ID: 15076141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
    Albertini MR; Hank JA; Gadbaw B; Kostlevy J; Haldeman J; Schalch H; Gan J; Kim K; Eickhoff J; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2012 Dec; 61(12):2261-71. PubMed ID: 22678096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
    Hank JA; Gan J; Ryu H; Ostendorf A; Stauder MC; Sternberg A; Albertini M; Lo KM; Gillies SD; Eickhoff J; Sondel PM
    Clin Cancer Res; 2009 Sep; 15(18):5923-30. PubMed ID: 19737959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.
    Yang RK; Kuznetsov IB; Ranheim EA; Wei JS; Sindiri S; Gryder BE; Gangalapudi V; Song YK; Patel V; Hank JA; Zuleger C; Erbe AK; Morris ZS; Quale R; Kim K; Albertini MR; Khan J; Sondel PM
    Clin Cancer Res; 2020 Jul; 26(13):3296-3306. PubMed ID: 32152202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
    Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
    Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
    Yamane BH; Hank JA; Albertini MR; Sondel PM
    Expert Opin Investig Drugs; 2009 Jul; 18(7):991-1000. PubMed ID: 19548853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
    Albertini MR; Yang RK; Ranheim EA; Hank JA; Zuleger CL; Weber S; Neuman H; Hartig G; Weigel T; Mahvi D; Henry MB; Quale R; McFarland T; Gan J; Carmichael L; Kim K; Loibner H; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2018 Oct; 67(10):1647-1658. PubMed ID: 30073390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.
    Connor JP; Cristea MC; Lewis NL; Lewis LD; Komarnitsky PB; Mattiacci MR; Felder M; Stewart S; Harter J; Henslee-Downey J; Kramer D; Neugebauer R; Stupp R
    BMC Cancer; 2013 Jan; 13():20. PubMed ID: 23320927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
    Shusterman S; London WB; Gillies SD; Hank JA; Voss SD; Seeger RC; Reynolds CP; Kimball J; Albertini MR; Wagner B; Gan J; Eickhoff J; DeSantes KB; Cohn SL; Hecht T; Gadbaw B; Reisfeld RA; Maris JM; Sondel PM
    J Clin Oncol; 2010 Nov; 28(33):4969-75. PubMed ID: 20921469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
    Danielli R; Patuzzo R; Di Giacomo AM; Gallino G; Maurichi A; Di Florio A; Cutaia O; Lazzeri A; Fazio C; Miracco C; Giovannoni L; Elia G; Neri D; Maio M; Santinami M
    Cancer Immunol Immunother; 2015 Aug; 64(8):999-1009. PubMed ID: 25971540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.
    Weide B; Martens A; Wistuba-Hamprecht K; Zelba H; Maier L; Lipp HP; Klumpp BD; Soffel D; Eigentler TK; Garbe C
    Cancer Immunol Immunother; 2017 Apr; 66(4):441-449. PubMed ID: 28008452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
    Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
    Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.
    Alpaugh RK; von Mehren M; Palazzo I; Atkins MB; Sparano JA; Schuchter L; Weiner LM; Dutcher JP
    Med Oncol; 1998 Sep; 15(3):191-8. PubMed ID: 9819796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.